Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07044362 | Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis | recruiting | N/A | 100 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07220018 | Colorectal Cancer Screening in the Homeless | recruiting | N/A | 588 | George Washington UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07255001 | Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life(PanFit) | recruiting | N/A | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | recruiting | Phase 3 | 700 | Incyte CorporationINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07367516 | Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 105 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07429487 | Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer(WATCH AND ACT) | recruiting | N/A | 98 | Centre Antoine LacassagneOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07500259 | Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC(COLOPan) | recruiting | — | 188 | Luxembourg Institute of HealthOTHER_GOV | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07540832 | A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC | not yet recruiting | Phase 1 / Phase 2 | 80 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07769853 | Iparomlimab and Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer(IT-CABLE) | not yet recruiting | N/A | 56 | Zhejiang UniversityOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07775209 | Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma(SSIBLING) | enrolling by invitation | Phase 2 | 24 | University of Vermont Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07776080 | Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07815392 | Preoperative Frailty and Postoperative Outcomes in Older Patients Undergoing Surgery for Gastrointestinal Cancer | recruiting | — | 100 | Van Training and Research HospitalOTHER_GOV | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819539 | Anthocyanin-Rich Berry Supplementation in Patients With Colorectal Cancer | completed | N/A | 70 | Jagiellonian UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819604 | Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 85 | Xijing HospitalOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07820644 | A Cohort Study (Risk Prediction of HCC in Patients With Chronic Liver Disease) | recruiting | — | 15,000 | Cai QingxianOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT01300143 | Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma(TACERTE) | completed | Phase 2 | 126 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01313442 | Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer | recruiting | — | 550 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02587247 | ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer(iTEP Colon) | completed | Phase 2 | 11 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02782949 | Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia | active not recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 2 | Sep 14, 2026 | clinicaltrials |
| NCT02869802 | Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis(PanGen) | recruiting | — | 190 | British Columbia Cancer AgencyOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03151564 | Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques | active not recruiting | N/A | 146 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03533582 | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | active not recruiting | Phase 3 | 537 | Children's Oncology GroupNETWORK | 6 | Sep 14, 2026 | clinicaltrials |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | suspended | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04166318 | Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study | active not recruiting | Phase 2 | 252 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04248452 | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body | active not recruiting | Phase 3 | 314 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04380545 | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer | recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy(SKYSCRAPER-07) | completed | Phase 3 | 760 | Hoffmann-La RocheINDUSTRY | 28 | Sep 14, 2026 | clinicaltrials |
| NCT04559139 | Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer | active not recruiting | Phase 2 / Phase 3 | 186 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04708067 | Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | active not recruiting | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04721132 | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | active not recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04858009 | Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05109468 | Assessment of Patients' Quality of Sexual Life After Anal Cancer Treatment(SEQUOIA) | completed | — | 46 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05132244 | Monitoring and Managing Glucose Levels in People With Pancreatic Cancer(PEGASUS) | recruiting | N/A | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05197322 | NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer(NEOPRISM-CRC) | active not recruiting | Phase 2 | 88 | University College, LondonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05799274 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors(RAD301) | active not recruiting | Phase 1 | 9 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05883644 | Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)(SIERRA) | active not recruiting | Phase 3 | 111 | AstraZenecaINDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT06134960 | NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor | recruiting | Phase 1 | 12 | Peking UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | recruiting | Phase 3 | 286 | Jazz PharmaceuticalsINDUSTRY | 25 | Sep 14, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials